IgGenix, a San Francisco-based biotech company, announced yesterday they had secured $40 million in Series B funding to bring a peanut allergy candidate to...
ADP101 is intended to treat patients with an allergy to one or more of peanut, almond, hazelnut, cashew, pistachio, pecan, walnut, milk, egg, cod, salmon, shrimp, wheat, soy, and sesame.
The company, which is already in phase 2 clinical trials with a treatment for celiac disease, has announced the FDA has accepted their Investigational New Drug (IND) application for evaluation of CNP-201, A treatment for peanut allergy. that reduces the need for strict peanut avoidance and reduces the potentially fatal health risks associated with peanut allergy.
By transplanting fecal microbes from healthy and food-allergic infants to germ-free mice (who do not possess a microbiome), investigators found that the healthy infant microbiota was protective against the development of food allergies.